A layered approach to raising public awareness of macular degeneration in Australia.
暂无分享,去创建一个
[1] P. Mitchell,et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials , 2009, British Journal of Ophthalmology.
[2] Philip J Rosenfeld,et al. Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[3] R. T. Smith,et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[4] D. Economics,et al. Eyes on the future: A clear outlook on Age-related Macular Degeneration , 2011 .
[5] Mark Michels,et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.